We, hence, conclude that VPA might function more effectively on metastatic prostate cancer than on non-metastatic prostate cancer and that the anticancer effect of VPA on prostate cells is, in part, mediated by the induction of NDRG1. Here, NDRG1 is linked to Familial prostate cancer.